同源康醫藥-B(02410)在研1類新藥甲磺酸艾多替尼片被國家藥品監督管理局藥品審評中心納入優先審評品種名單

智通財經

01/29

智通財經APP訊，同源康醫藥-B(02410)公布，公司在研1類新藥甲磺酸艾多替尼片(TY-9591片)被國家藥品監督管理局(NMPA)藥品審評中心(CDE)納入優先審評品種名單。

甲磺酸艾多替尼片(TY-9591片)擬定的適應症為具有EGFR外顯子19缺失(19DEL) 或外顯子21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患者的一線治療。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2607702571"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607702571\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607702571?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-29 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607702571","market":"sh","top_or_hot":-1,"title":"同源康醫藥-B(02410)在研1類新藥甲磺酸艾多替尼片被國家藥品監督管理局藥品審評中心納入優先審評品種名單","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/02410\">同源康醫藥-B</a>(02410)公布，公司在研1類新藥甲磺酸艾多替尼片(TY-9591片)被國家藥品監督管理局(NMPA)藥品審評中心(CDE)納入優先審評品種名單。</p><p>甲磺酸艾多替尼片(TY-9591片)擬定的適應症為具有EGFR外顯子19缺失(19DEL) 或外顯子21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患者的一線治療。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康醫藥-B(02410)在研1類新藥甲磺酸艾多替尼片被國家藥品監督管理局藥品審評中心納入優先審評品種名單</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康醫藥-B(02410)在研1類新藥甲磺酸艾多替尼片被國家藥品監督管理局藥品審評中心納入優先審評品種名單\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-01-29 17:08</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/02410\">同源康醫藥-B</a>(02410)公布，公司在研1類新藥甲磺酸艾多替尼片(TY-9591片)被國家藥品監督管理局(NMPA)藥品審評中心(CDE)納入優先審評品種名單。</p><p>甲磺酸艾多替尼片(TY-9591片)擬定的適應症為具有EGFR外顯子19缺失(19DEL) 或外顯子21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患者的一線治療。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1399178.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"醫藥","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1399178.html","article_id":"2607702571","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607702571","pubTimestamp":1769677696,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，同源康醫藥-B(02410)公布，公司在研1類新藥甲磺酸艾多替尼片(TY-9591片)被國家藥品監督管理局(NMPA)藥品審評中心(CDE)納入優先審評品種名單。甲磺酸艾多替尼片(TY-9591片)擬定的適應症為具有EGFR外顯子19缺失(19DEL) 或外顯子21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患者的一線治療。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","02410":"同源康医药-B","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Tongyuankang Pharmaceutical-B (02410) Class 1 new drug Idotinib Mesylate Tablets under development was included in the list of priority review varieties by the Drug Evaluation Center of the State Medical Products Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5,"02410":1.5},"content_text":"智通財經APP訊，同源康醫藥-B(02410)公布，公司在研1類新藥甲磺酸艾多替尼片(TY-9591片)被國家藥品監督管理局(NMPA)藥品審評中心(CDE)納入優先審評品種名單。甲磺酸艾多替尼片(TY-9591片)擬定的適應症為具有EGFR外顯子19缺失(19DEL) 或外顯子21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患者的一線治療。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}